8-K: DBV Technologies Confirms FDA Alignment on Accelerated Approval for Viaskin Peanut Patch in Toddlers

DBV Technologies has secured FDA alignment on an accelerated approval pathway for its Viaskin Peanut patch in toddlers aged 1-3 years, paving the way for a potential BLA submission in 2026.

Summary

• DBV Technologies has received confirmation from the FDA regarding an accelerated approval pathway for their Viaskin Peanut patch for toddlers aged 1 to 3 years.
• The FDA has agreed that the efficacy data from the Phase 3 EPITOPE study can serve as an intermediate clinical endpoint, fulfilling a key requirement for accelerated approval.
• The company plans to initiate the COMFORT Toddlers study in the second quarter of 2025, which will assess the safety and adhesion of the commercial Viaskin Peanut patch.
• A post-marketing confirmatory study will be required, using the commercial patch, and will be initiated at the time of the BLA submission.
• The BLA submission for the Viaskin Peanut patch in toddlers is anticipated in the second half of 2026.
• The COMFORT Toddlers study will enroll approximately 480 subjects across multiple countries and will include a six-month double-blind, placebo-controlled phase followed by an optional 18-month open-label treatment phase.
• The company has made modifications to the Viaskin Peanut patch to improve ease of use and manufacturing, but these changes were deemed by the FDA to constitute a different product from the clinical patch used in the EPITOPE study.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the confirmed accelerated approval pathway and clear next steps. The company has successfully navigated regulatory hurdles and is progressing towards BLA submission. However, the need for a post-marketing confirmatory study introduces some uncertainty.

Positives

• The FDA's confirmation of an accelerated approval pathway significantly reduces regulatory risk for the Viaskin Peanut patch program.
• The acceptance of the EPITOPE study data as an intermediate clinical endpoint streamlines the approval process.
• The company has aligned with the FDA on key study design elements for the COMFORT Toddlers study, including study size and wear time collection methodology.
• The company has a clear path forward for two distinct BLA submissions across age groups and an MAA in Europe.
• The commercial patch has been used in a significant number of subjects with no clinically relevant differences in efficacy or safety compared to the clinical patch.

Negatives

• The FDA considers the commercial Viaskin Peanut patch a different product from the clinical patch used in the EPITOPE study, requiring a post-marketing confirmatory study.
• The post-marketing confirmatory study will need to be initiated at the time of the BLA submission, potentially delaying the commercial launch.
• The company will need to conduct a new study (COMFORT Toddlers) to generate additional safety and adhesion data for the commercial patch.

Risks

• The success of the Viaskin Peanut patch is dependent on the results of the COMFORT Toddlers study and the post-marketing confirmatory study.
• There are inherent risks associated with clinical trials and regulatory approvals.
• The company's ability to successfully execute on its budget discipline measures could impact the program.
• The company is subject to uncertainties associated with research and development, clinical trials, and related regulatory reviews and approvals.

Future Outlook

DBV Technologies is focused on executing the remaining studies to support two distinct BLA submissions for the Viaskin Peanut patch across different age groups and an MAA in Europe. The company anticipates submitting the BLA for the toddler indication in the second half of 2026.

Management Comments

• Daniel Tass, Chief Executive Officer, stated that they believe they have decreased the regulatory pathway risk of their programs.
• Daniel Tass also mentioned that DBV can now fully focus on executing the remaining studies that will support two distinct BLAs across age groups and an MAA in Europe.
• Dr. Julie Wang, MD, Global Principal Investigator for the COMFORT Toddlers study, stated that Viaskin Peanut, if approved, would offer a much-needed alternative treatment option for patients and caregivers.

Industry Context

This announcement is significant for the food allergy treatment space, as it provides a clear regulatory pathway for a novel therapy. The accelerated approval pathway could expedite the availability of a new treatment option for young children with peanut allergies, addressing a significant unmet medical need.

Comparison to Industry Standards

• The accelerated approval pathway is a common regulatory strategy for drugs addressing serious conditions with unmet needs, similar to other approvals in the pharmaceutical industry.
• The use of an intermediate clinical endpoint from a previous study (EPITOPE) is a strategy used by other companies to expedite the approval process.
• The requirement for a post-marketing confirmatory study is standard practice for accelerated approvals, ensuring continued monitoring of efficacy and safety.
• The study design of COMFORT Toddlers, including the use of a double-blind, placebo-controlled design, is consistent with industry standards for clinical trials.

Stakeholder Impact

• Shareholders will likely view the news positively due to the reduced regulatory risk and clear path to potential approval.
• Patients and caregivers will benefit from the potential availability of a new treatment option for peanut allergies.
• Employees will be involved in the execution of the upcoming clinical trials and regulatory submissions.

Next Steps

• Initiate the COMFORT Toddlers study in the second quarter of 2025.
• Conduct the post-marketing confirmatory study.
• Submit the BLA for the Viaskin Peanut patch in toddlers in the second half of 2026.

Key Dates

Keywords

Viaskin Peanut patch, Accelerated Approval, FDA, Food Allergy, COMFORT Toddlers, BLA, EPITOPE study, Post-marketing confirmatory study, Toddlers, DBV Technologies